Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dimerix Limited (DXB.AX)
Fitzroy, VIC, AU
Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient. The company's leading therapeutic candidate, DMX-200, is currently undergoing extensive clinical evaluation, including two separate Phase 3 trials targeting respiratory complications linked to COVID-19. DMX-200 is also in a distinct Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS), a severe kidney disorder, and is being developed for the treatment of diabetic kidney disease. Additionally, Dimerix is advancing DMX-700, which is intended for chronic obstructive pulmonary disease (COPD). The company's corporate headquarters are located in Fitzroy, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.71% | -9.76% | -19.57% | -61.05% | -64.76% | -66.36% | -67.83% | -39.34% | -39.34% | -39.34% | -39.34% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+115.0% ★ Q4'25: +1,490.8% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+37.4% ★ Q4'25: -62.2% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+2,613.0% Q4'25: -1,410.9% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-2,896.7% Q4'25: -1,026.7% (vs Q4'23)
-
ROIC Biotechnology: -16.1%— Q4'25: +160.7% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+23.7% Q4'25: +47.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.34M
est: 1.10M (+112.8%)
|
4.44M
est: 1.90M (+133.7%)
|
6.46M
est: 1.10M (+487.5%)
|
36.8K
est: 1.90M (-98.1%)
|
583.5K
est: 4.10M (-85.8%)
|
1.25M
est: 8.10M (-84.5%)
|
7.20M
7.20M – 7.20M
-11.1% YoY
|
7.20M
7.20M – 7.20M
+0.0% YoY
|
16.50M
16.50M – 16.50M
+129.2% YoY
|
| EBITDA |
-6.82M
est: -1.10M (-519.9%)
|
-10.02M
est: -7.76M (-29.1%)
|
-16.47M
est: -1.10M (-1,397.5%)
|
-22.68M
est: -1.90M (-1,093.7%)
|
-24.96M
est: -4.10M (-508.8%)
|
-36.22M
est: -8.10M (-347.1%)
|
-7.20M
-7.20M – -7.20M
+11.1% YoY
|
-7.20M
-7.20M – -7.20M
+0.0% YoY
|
-16.50M
-16.50M – -16.50M
-129.2% YoY
|
| EBIT |
-6.83M
est: -1.10M (-521.1%)
|
-10.07M
est: -7.76M (-29.7%)
|
-16.52M
est: -1.10M (-1,402.0%)
|
-22.74M
est: -1.90M (-1,096.7%)
|
-25.01M
est: -4.10M (-509.9%)
|
-36.34M
est: -8.10M (-348.7%)
|
-7.20M
-7.20M – -7.20M
+11.1% YoY
|
-7.20M
-7.20M – -7.20M
+0.0% YoY
|
-16.50M
-16.50M – -16.50M
-129.2% YoY
|
| Net Income |
-4.49M
est: -9.91M (+54.7%)
|
-6.37M
est: -7.76M (+17.9%)
|
-10.49M
est: -9.91M (-5.8%)
|
-13.80M
est: -16.52M (+16.4%)
|
-17.08M
est: -12.89M (-32.5%)
|
-13.25M
est: -17.37M (+23.7%)
|
-21.86M
-21.86M – -21.86M
-25.8% YoY
|
-13.45M
-13.45M – -13.45M
+38.5% YoY
|
-5.04M
-5.04M – -5.04M
+62.5% YoY
|
| SGA |
1.30M
est: 16.79M (-92.3%)
|
1.60M
est: 29.00M (-94.5%)
|
2.57M
est: 16.79M (-84.7%)
|
2.35M
est: 29.00M (-91.9%)
|
4.55M
est: 62.58M (-92.7%)
|
4.89M
est: 123.64M (-96.0%)
|
109.90M
109.90M – 109.90M
-11.1% YoY
|
109.90M
109.90M – 109.90M
+0.0% YoY
|
251.85M
251.85M – 251.85M
+129.2% YoY
|
| EPS |
-0.03
est: -0.02 (-45.3%)
|
-0.03
est: -0.03 (-7.2%)
|
-0.04
est: -0.02 (-97.9%)
|
-0.04
est: -0.03 (-43.8%)
|
-0.04
est: -0.02 (-63.9%)
|
-0.02
est: -0.03 (+23.9%)
|
-0.04
-0.04 – -0.04
-25.8% YoY
|
-0.02
-0.02 – -0.02
+38.5% YoY
|
-0.01
-0.01 – -0.01
+62.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nina Webster | Chief Executive Officer, MD & Director | 880.5K | — |
| David Everett Fuller MBBS | Chief Medical Officer | 481.9K | — |
| Robert Shepherd | Chief Operating Officer | 409.0K | male |
| Kevin Donald George Pfleger | Chief Scientific Advisor | — | male |
| Michael Tonroe | Chief Financial Officer & Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DXB.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
